Based on the company's latest reports for June 2026, the current 12-month EPS is $12.41. DaVita's earnings per share in 2025 was reported at $10.06, marking a decline from $11.02 in 2024. In the quarterly report ending on Jun 30, 2026, DVA's earnings per share amounted to $4.1.
DaVita had an yealy earnings per share of $10.06, showing a decline of 8.7% from $11.02 recorded in 2024. The quarterly earnings per share for the period ending Jun 30, 2026, was $4.1, showing a 56.5% increase compared to the same quarter last year. The trailing twelve months EPS for DVA is $12.41 as of June 2026. DaVita's full-year EPS for 2024 was $11.02, a 44.6% rise compared to the previous year.
In the past 12 months, DaVita has recorded an earnings per share growth rate of 56.5% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 18.6% per year. In the last five years, the company had an average annual EPS growth of 9.3%. When assessed over a ten-year period, DVA's average EPS annual growth was 23%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| UHS Universal Health Services Inc - Class B | 7.15 | 36.5% | 36.4% | 16.2% |
| THC Tenet Healthcare Corp | 10.75 | -52.7% | 59.6% | 32.7% |
| MD Pediatrix Medical Group Inc | 12.47 | 265.5% | 35.6% | N/A |
| DVA DaVita Inc | 14.01 | -8.7% | 18.6% | 9.3% |
| LH Laboratory Corp Of America Holdings | 27.64 | 18.6% | -9.1% | -8% |
All data is based on quarterly TTM periods, unless otherwise specified.